KRAS and neoplasm: This metabolic adaptation was also evident in analysis of RNA-seq data from organoids derived from PDAC patients treated with FOLFIRINOX, a combination of chemotherapeutic agents (folinic acid, fluorouracil, irinotecan hydrochloride, oxaliplatin) used to treat tumours with KRAS mutations, including PDAC.